EMERYVILLE, Calif. & NEW YORK--(EON: Enhanced Online News)--KineMed Inc. (www.kinemed.com) and CHDI Foundation, Inc. announced today a collaboration to investigate the role of the metabolism of cholesterol and other lipids in Huntington’s disease (HD). Research leading up to this study suggests that the homeostatic processes that control the balance of cholesterol in the brain are altered in HD patients.
“Changes in sterols are one of a number of alterations that research has identified in HD patients. Our collaboration with KineMed will help us further explore this and could lead us to additional targets for therapeutic intervention as well as handles on disease progression in the future”
The collaboration will utilize KineMed’s extensive experience in cholesterol metabolic studies and will quantify physiologic and pathologic brain lipid synthesis in HD. KineMed aims to develop lipid kinetic biomarkers, including the dynamics of cholesterol, phospholipids and galactosylceramide in the brain, as well as the synthesis of plasma 24-hydroxy cholesterol. If successful, these kinetic biomarkers will be used as indicators of disease progression and to evaluate the effectiveness of therapeutic interventions.
“Developing a biomarker that measures cholesterol metabolism in the living brain from a blood sample is a key to developing better medicines,” said Dr. Scott Turner, EVP, R&D at KineMed, “Altered cholesterol metabolism is also implicated as a pathogenic mechanism in other CNS diseases such as Alzheimer’s, Parkinson’s and ALS, as well as Huntington’s.”
“Changes in sterols are one of a number of alterations that research has identified in HD patients. Our collaboration with KineMed will help us further explore this and could lead us to additional targets for therapeutic intervention as well as handles on disease progression in the future,” said Dr. Deanna Marchionini, Director, Discovery Biology at CHDI.
About CHDI Foundation, Inc.
CHDI Foundation, Inc. is a privately funded, not-for-profit, biomedical research organization that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington’s disease (HD). As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus.
More information about CHDI can be found at http://www.chdifoundation.org
About KineMed, Inc.
KineMed, based in California, is a world-leader and innovator in the identification and measurement of the biochemical processes that cause disease. KineMed’s core, patented, dynamic proteomics and kinetic biomarkers technology platforms accelerate and lower the cost of diagnostic and therapeutic R&D.
KineMed is constantly seeking to expand its portfolio of collaborations with pharmaceutical, CRO, histopathology, diagnostics, medical instruments and biotechnology partners. Established programs with premier pharmaceutical collaborators address critical challenges facing drug discovery:
- Focus on causes rather than symptoms: Generating pivotal knowledge for developing blockbuster drugs, by targeting underlying biochemical causes
- Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context
- Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
- Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine
More information about KineMed can be found at http://www.kinemed.com